# Mays Cancer Center at UT Health San Antonio

Source: https://onco.cc/institutions/mays-cancer-center/  
OnCo record `mays-cancer-center` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mays Cancer Center in San Antonio, NCI-designated since 1991, hosts the San Antonio Breast Cancer Symposium and descends from the CTRC phase 1 institute where Daniel Von Hoff ran early trials of gemcitabine and nab-paclitaxel; it serves South Texas's predominantly Latino population.

## Summary

Mays Cancer Center descends from the Cancer Therapy & Research Center, NCI-designated since 1991, whose Institute for Drug Development under Daniel Von Hoff conducted early trials of gemcitabine and nab-paclitaxel among other agents. UT Health San Antonio founded the San Antonio Breast Cancer Symposium in 1977, now the world's largest breast cancer meeting, co-hosted with the AACR and Baylor's Smith Breast Center. The centre serves South Texas's predominantly Latino population, with Amelie Ramirez's Salud America! programme addressing Latino cancer disparities, and hosts the Greehey Children's Cancer Research Institute. It is an MD Anderson affiliate and has strengths in myeloproliferative neoplasms and breast oncology.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: CTRC; Cancer Therapy & Research Center
- City: San Antonio, TX, US
- Type: cancer-center
- NCI designation: clinical
- Website: https://cancer.uthscsa.edu

## Sources

- Mays Cancer Center: https://cancer.uthscsa.edu
- SABCS: https://www.sabcs.org

## Connected records

- collections: [NCI-Designated Cancer Centers](https://onco.cc/collections/nci-cancer-centers/), [San Antonio Breast Cancer Symposium](https://onco.cc/collections/src-sabcs/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- institutions: [American Association for Cancer Research (AACR)](https://onco.cc/institutions/aacr/), [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- trials: [Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)](https://onco.cc/trials/nct01906385/)
- people: [Lei Zheng](https://onco.cc/people/lei-zheng/)
- bottlenecks: [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)

---
JSON: https://onco.cc/api/v1/entities/mays-cancer-center.json